Hoechst Pakistan Limited (PSX: HPL)

Market Cap	25.16B
Revenue (ttm)	26.01B
Net Income (ttm)	1.62B
Shares Out	9.64M
EPS (ttm)	167.77
PE Ratio	15.55
Forward PE	n/a
Dividend	50.00 (1.92%)
Ex-Dividend Date	n/a

Volume	506
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	900.00 - 2,650.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About Hoechst Pakistan

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its antibiotic, cardiology, diabetes, pain and allergy, and other products under Flagyl, Clexane, NO-SPA, Lantus, Amaryl, Claforan, Haemaccel, Enterogermina, and Plavix brands. It also offers various shampoos under the Selsun Blue brand name. The company was formerly known as Sanofi-Aventis Pakistan Limited and changed its name to Hoechst Pakistan Limited in September 2...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 734
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HPL

Financial Performance

In 2023, Hoechst Pakistan's revenue was 21.37 billion, an increase of 15.14% compared to the previous year's 18.56 billion. Earnings were 360.81 million, an increase of 116.33%.